Industry Trend Analysis - Limited Potential For Innovative Drugmaker Medicine Sales - MAR 2018


BMI View : Cote d'Ivoire's pharmaceutical market will remain challenging for multinational firms and presents limited opportunities for innovative drugmakers over the coming years. Opportunities will favour the domestic competitive landscape focused on the generic drug sub-sector as low purchasing power, weak patent laws and a poorly enforced regulatory framework deter the entry of higher-value medicines.

Cote d'Ivoire's pharmaceutical sector will remain underdeveloped on a global scale for the foreseeable future as the nascent regulatory environment and general lack of healthcare coverage deter any meaningful investment by multinational firms. While Cote d'Ivoire has a budding pharmaceutical manufacturing sector that meets Good Manufacturing Practices (GMP) standards, the goal to become West Africa's hub for medicine production is highly ambitious over the near term, with the majority of drugmakers opting to use Nigeria as their preferred operational base. The table below illustrates the main multinational drugmaker activity in Cote d'Ivoire, which highlights the steps being taken by foreign firms to boost the commercial viability of medicine programmes in a challenging market.

Risk Profile Will Limit Innovative Drugmaker Gains

This article is part of our Middle East & Africa coverage. To access this article subscribe now or sign up for free trial